Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is a promising biotechnology company with a positive outlook, thanks to their innovative Dually Derivatized Oligochitosan (DDX) platform and current focus on developing a mucosal gene therapy for Non-Muscle Invasive Bladder Cancer (NMIBC). Detalimogene, their lead candidate, has shown potential with a 54% any-time complete response rate and a low incidence of treatment-related adverse events, making it a strong candidate for FDA approval. The company also has a potential upside with their combination of detalimogene and surfactant bladder wash, which has shown improved transfection and higher expression of IL-12. Investors will be looking for an update on the durability of the response to detalimogene in late 2026 to further assess the commercial potential of the drug.

Bears say

enGene Therapeutics is facing significant financial challenges due to its high operating expenses and low cash reserves. The company's net loss has increased, driven by higher operating expenses, and its cash, cash equivalents, and marketable securities are limited. Additionally, while enGene's non-viral gene therapy platform shows potential in the NMIBC market, its competitors have more promising data and it remains to be seen how the FDA and payers will view the company's product. These uncertainties make it difficult to have a positive outlook on the company's stock.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.